These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 29731121)

  • 1. Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the EVEREST Trial).
    Vaduganathan M; Patel RB; Mentz RJ; Subacius H; Chatterjee NA; Greene SJ; Ambrosy AP; Maggioni AP; Udelson JE; Swedberg K; Konstam MA; O'Connor CM; Butler J; Gheorghiade M; Zannad F
    Am J Cardiol; 2018 Jul; 122(2):255-260. PubMed ID: 29731121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.
    Lanfear DE; Sabbah HN; Goldsmith SR; Greene SJ; Ambrosy AP; Fought AJ; Kwasny MJ; Swedberg K; Yancy CW; Konstam MA; Maggioni AP; Zannad F; Gheorghiade M;
    Circ Heart Fail; 2013 Jan; 6(1):47-52. PubMed ID: 23239836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
    Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
    JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of an implantable cardioverter-defibrillator in patients with diabetes and heart failure and reduced ejection fraction.
    Rørth R; Dewan P; Kristensen SL; Jhund PS; Petrie MC; Køber L; McMurray JJV
    Clin Res Cardiol; 2019 Aug; 108(8):868-877. PubMed ID: 30689020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of the 6-min walk distance to identify variations in treatment benefits from implantable cardioverter-defibrillator and amiodarone: results from the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial).
    Fishbein DP; Hellkamp AS; Mark DB; Walsh MN; Poole JE; Anderson J; Johnson G; Lee KL; Bardy GH;
    J Am Coll Cardiol; 2014 Jun; 63(23):2560-2568. PubMed ID: 24727258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in Dyspnea Status During Hospitalization and Postdischarge Health-Related Quality of Life in Patients Hospitalized for Heart Failure: Findings From the EVEREST Trial.
    Ambrosy AP; Khan H; Udelson JE; Mentz RJ; Chioncel O; Greene SJ; Vaduganathan M; Subacuis HP; Konstam MA; Swedberg K; Zannad F; Maggioni AP; Gheorghiade M; Butler J
    Circ Heart Fail; 2016 May; 9(5):. PubMed ID: 27140204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gender does not affect postdischarge outcomes in patients hospitalized for worsening heart failure with reduced ejection fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan [EVEREST] Trial).
    Shah AN; Mentz RJ; Gheorghiade M; Kwasny MJ; Fought AJ; Zannad F; Swedberg K; Maggioni AP; Konstam MA
    Am J Cardiol; 2012 Dec; 110(12):1803-8. PubMed ID: 22999071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of primary prevention implantable cardioverter-defibrillator use in heart failure with reduced ejection fraction: impact of the predicted risk of sudden cardiac death and all-cause mortality.
    Schrage B; Lund LH; Benson L; Dahlström U; Shadman R; Linde C; Braunschweig F; Levy WC; Savarese G
    Eur J Heart Fail; 2022 Jul; 24(7):1212-1222. PubMed ID: 35502681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sudden Cardiac Death in Patients With Ischemic Heart Failure Undergoing Coronary Artery Bypass Grafting: Results From the STICH Randomized Clinical Trial (Surgical Treatment for Ischemic Heart Failure).
    Rao MP; Al-Khatib SM; Pokorney SD; She L; Romanov A; Nicolau JC; Lee KL; Carson P; Selzman CH; Stepinska J; Cleland JG; Tungsubutra W; Desvigne-Nickens PM; Sueta CA; Siepe M; Lang I; Feldman AM; Yii M; Rouleau JL; Velazquez EJ;
    Circulation; 2017 Mar; 135(12):1136-1144. PubMed ID: 28154006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sudden cardiac death after acute heart failure hospital admission: insights from ASCEND-HF.
    Pokorney SD; Al-Khatib SM; Sun JL; Schulte P; O'Connor CM; Teerlink JR; Armstrong PW; Ezekowitz JA; Starling RC; Voors AA; Velazquez EJ; Hernandez AF; Mentz RJ
    Eur J Heart Fail; 2018 Mar; 20(3):525-532. PubMed ID: 29266564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implantable cardioverter-defibrillators in heart failure patients with reduced ejection fraction and diabetes.
    Sharma A; Al-Khatib SM; Ezekowitz JA; Cooper LB; Fordyce CB; Michael Felker G; Bardy GH; Poole JE; Thomas Bigger J; Buxton AE; Moss AJ; Friedman DJ; Lee KL; Steinman R; Dorian P; Cappato R; Kadish AH; Kudenchuk PJ; Mark DB; Peterson ED; Inoue LYT; Sanders GD
    Eur J Heart Fail; 2018 Jun; 20(6):1031-1038. PubMed ID: 29761861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.
    Greene SJ; Gheorghiade M; Vaduganathan M; Ambrosy AP; Mentz RJ; Subacius H; Maggioni AP; Nodari S; Konstam MA; Butler J; Filippatos G;
    Eur J Heart Fail; 2013 Dec; 15(12):1401-11. PubMed ID: 23845795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of documented history of coronary artery disease on outcomes in patients admitted for worsening heart failure with reduced ejection fraction in the EVEREST trial.
    Mentz RJ; Allen BD; Kwasny MJ; Konstam MA; Udelson JE; Ambrosy AP; Fought AJ; Vaduganathan M; O'Connor CM; Zannad F; Maggioni AP; Swedberg K; Bonow RO; Gheorghiade M
    Eur J Heart Fail; 2013 Jan; 15(1):61-8. PubMed ID: 22968743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial).
    Greene SJ; Vaduganathan M; Lupi L; Ambrosy AP; Mentz RJ; Konstam MA; Nodari S; Subacius HP; Fonarow GC; Bonow RO; Gheorghiade M;
    Am J Cardiol; 2013 Feb; 111(4):574-81. PubMed ID: 23206923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of patients at risk of sudden cardiac death in congenital heart disease: The PRospEctiVE study on implaNTable cardIOverter defibrillator therapy and suddeN cardiac death in Adults with Congenital Heart Disease (PREVENTION-ACHD).
    Vehmeijer JT; Koyak Z; Leerink JM; Zwinderman AH; Harris L; Peinado R; Oechslin EN; Robbers-Visser D; Groenink M; Boekholdt SM; de Winter RJ; Oliver JM; Bouma BJ; Budts W; Van Gelder IC; Mulder BJM; de Groot JR
    Heart Rhythm; 2021 May; 18(5):785-792. PubMed ID: 33465514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sudden cardiac death risk prediction in heart failure with preserved ejection fraction.
    Adabag S; Langsetmo L
    Heart Rhythm; 2020 Mar; 17(3):358-364. PubMed ID: 31838199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Where patients with mild to moderate heart failure die: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).
    Olshansky B; Wood F; Hellkamp AS; Poole JE; Anderson J; Johnson GW; Boineau R; Domanski MJ; Mark DB; Lee KL; Bardy GH;
    Am Heart J; 2007 Jun; 153(6):1089-94. PubMed ID: 17540216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic significance of heart rate in patients hospitalized for heart failure with reduced ejection fraction in sinus rhythm: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study With Tolvaptan) trial.
    Greene SJ; Vaduganathan M; Wilcox JE; Harinstein ME; Maggioni AP; Subacius H; Zannad F; Konstam MA; Chioncel O; Yancy CW; Swedberg K; Butler J; Bonow RO; Gheorghiade M;
    JACC Heart Fail; 2013 Dec; 1(6):488-96. PubMed ID: 24622000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Implantable Cardioverter Defibrillators With Survival in Patients With and Without Improved Ejection Fraction: Secondary Analysis of the Sudden Cardiac Death in Heart Failure Trial.
    Adabag S; Patton KK; Buxton AE; Rector TS; Ensrud KE; Vakil K; Levy WC; Poole JE
    JAMA Cardiol; 2017 Jul; 2(7):767-774. PubMed ID: 28724134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial.
    Ambrosy AP; Vaduganathan M; Mentz RJ; Greene SJ; Subačius H; Konstam MA; Maggioni AP; Swedberg K; Gheorghiade M
    Am Heart J; 2013 Feb; 165(2):216-25. PubMed ID: 23351825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.